Karyopharm Therapeutics Inc.Karyopharm Therapeutics Inc.Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪115.32 M‬USD
‪−143.10 M‬USD
‪146.03 M‬USD
‪110.07 M‬
Beta (1Y)

About Karyopharm Therapeutics Inc.

Richard A. Paulson
Employees (FY)
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
Revenue to profit conversion
Debt level and coverage
Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of KPTI is 0.9366 USD — it has increased by 1.21% in the past 24 hours. Watch Karyopharm Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Karyopharm Therapeutics Inc. stocks are traded under the ticker KPTI.
KPTI stock has fallen by 5.39% compared to the previous week, the month change is a 3.44% fall, over the last year Karyopharm Therapeutics Inc. has showed a 41.83% decrease.
We've gathered analysts' opinions on Karyopharm Therapeutics Inc. future price: according to them, KPTI price has a max estimate of 8.00 USD and a min estimate of 2.00 USD. Watch KPTI chart and read a more detailed Karyopharm Therapeutics Inc. stock forecast: see what analysts think of Karyopharm Therapeutics Inc. and suggest that you do with its stocks.
KPTI reached its all-time high on Dec 8, 2014 with the price of 49.0050 USD, and its all-time low was 0.6174 USD and was reached on Dec 11, 2023. View more price dynamics on KPTI chart.
See other stocks reaching their highest and lowest prices.
KPTI stock is 4.95% volatile and has beta coefficient of 1.50. Track Karyopharm Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Karyopharm Therapeutics Inc. there?
Today Karyopharm Therapeutics Inc. has the market capitalization of ‪115.32 M‬, it has increased by 19.42% over the last week.
Yes, you can track Karyopharm Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Karyopharm Therapeutics Inc. is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
KPTI earnings for the last quarter are −0.32 USD per share, whereas the estimation was −0.33 USD resulting in a 4.15% surprise. The estimated earnings for the next quarter are −0.30 USD per share. See more details about Karyopharm Therapeutics Inc. earnings.
Karyopharm Therapeutics Inc. revenue for the last quarter amounts to ‪33.13 M‬ USD, despite the estimated figure of ‪34.48 M‬ USD. In the next quarter, revenue is expected to reach ‪36.21 M‬ USD.
KPTI net income for the last quarter is ‪−37.36 M‬ USD, while the quarter before that showed ‪−41.84 M‬ USD of net income which accounts for 10.70% change. Track more Karyopharm Therapeutics Inc. financial stats to get the full picture.
No, KPTI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 24, 2024, the company has 325.00 employees. See our rating of the largest employees — is Karyopharm Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Karyopharm Therapeutics Inc. EBITDA is ‪−132.07 M‬ USD, and current EBITDA margin is −88.34%. See more stats in Karyopharm Therapeutics Inc. financial statements.
Like other stocks, KPTI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Karyopharm Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Karyopharm Therapeutics Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Karyopharm Therapeutics Inc. stock shows the sell signal. See more of Karyopharm Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.